IP Library › Granted Patent US 12,404,306
Granted Patent B2
US 12,404,306 · App. 16/978,573 · Granted Sep 2, 2025

Human papillomavirus vaccines and uses of the same

Inventors: Douglas E. Brough (Germantown, MD); Cheryl G. Bolinger (Germantown, MD); Ramya Yarlagadda (Blacksburg, VA); Vinodhbabu Kurella (Blacksburg, VA); Prabakaran Ponraj (Blacksburg, VA); Simon Metenou (Germantown, MD); Kuan-Fu Ding (Blacksburg, VA)
Assignee: Precigen, Inc.
C07K14/005A61K39/12A61K39/292A61K48/0066C07K14/02C12N7/00C12N15/861C07K2319/33C12N2710/20022C12N2710/20034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,306
App. No.
16/978,573
Granted
Sep 2, 2025
Kind
B2
Abstract

Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.

Claims (12)

1. A polynucleotide encoding a polypeptide construct comprising the amino acid sequence of SEQ ID NO: 52 or 54.

2. A vector comprising the polynucleotide of claim 1 .

3. The vector of claim 2 , wherein the vector is an adenoviral vector.

4. The polynucleotide of claim 1 , wherein the polypeptide construct comprises the amino acid sequence of SEQ ID NO: 54.

5. The polynucleotide of claim 1 , wherein the polypeptide construct comprises the amino acid sequence of SEQ ID NO: 52.

6. The vector of claim 3 , wherein the adenoviral vector is a gorilla adenoviral vector.

7. The vector of claim 6 , wherein the gorilla adenoviral vector does not comprise an E1 region.

8. The vector of claim 6 , wherein the gorilla adenoviral vector does not comprise an E4 region.

9. The vector of claim 6 , wherein the gorilla adenoviral vector does not comprise an E1 region or an E4 region.

10. The vector of claim 6 , wherein the gorilla adenoviral vector is a GC46 vector.

11. The vector of claim 6 , wherein the polynucleotide is under the control of an immediate early cytomegalovirus (CMV) promoter.

12. A method of vaccinating a subject against human papilloma virus, the method comprising administering to the subject the vector of claim 6 .

Assignments (3)
PATENT SECURITY AGREEMENT Recorded Sep 3, 2025
From: PRECIGEN, INC.; GENVEC LLC; PRECIGEN ACTOBIO, INC.; EXEMPLAR GENETICS, LLC
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072828/0564 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: PGEN THERAPEUTICS, INC.
To: PRECIGEN, INC.
Reel/Frame 061733/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2021
From: BROUGH, DOUGLAS E.; BOLINGER, CHERYL G.; YARLAGADDA, RAMYA; KURELLA, VINODHBABU; PONRAJ, PRABAKARAN; METENOU, SIMON; DING, KUAN-FU
To: PRECIGEN, INC.
Reel/Frame 058119/0766 →